Dana Farber PLGA
  • Home
  • About
  • Team
  • Research
  • Publications
  • News
  • Contact
  • Support
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

Targeting BRAF in pediatric brain tumors

Targeting BRAF in pediatric brain tumors

January 1, 2014

Targeting BRAF in pediatric brain tumors
Am Soc Clin Oncol Educ Book. 2014:e436-40.
Share this entry
  • Share on Facebook
  • Share on X
  • Share on LinkedIn
  • Share by Mail
https://www.danafarberplga.org/wp-content/uploads/2026/07/newlogo14-1030x129.png 0 0 Tam https://www.danafarberplga.org/wp-content/uploads/2026/07/newlogo14-1030x129.png Tam2014-01-01 00:00:232020-04-22 19:41:33Targeting BRAF in pediatric brain tumors

Research

  • cancer cells
    Tumor MicroenvironmentMarch 26, 2020 - 6:49 pm
  • Clinical Trials and Tissue Banking
    Clinical Trials and Tissue BankingDecember 11, 2018 - 5:19 pm
  • Dr. Sarah Buhrlage in her lab
    Drug DevelopmentDecember 11, 2018 - 5:18 pm
  • Illustration of a method of DNA sequencing. Image background seamless.
    GenomicsMay 11, 2018 - 5:16 pm
Search Search
DF PLAG logo
New Patient Coordinator
PLGA Fund
DF PLAG Harvard logo
© 2020 Dana Farber PLGA. All rights reserved. Site by Academic Web Pages.
Link to: Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. Link to: Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain... Link to: Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Link to: Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial...
Scroll to top Scroll to top Scroll to top